Autoimmune polyendocrine syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
Effective measures for the [[primary prevention]] of autoimmune polyendocrine syndrome (APS) include [[patient education]] and [[[[Screening (medicine)|screening]]. Autoimmune polyendocrine syndrome may be [[inherited]] in [[autosomal recessive]] (APS type 1), [[autosomal dominant]] (APS type 2) or [[X linked inheritance|X linked]] fashion (APS type 3) and therefore educating relatives about presence of APS in [[family]] is necessary. In addition, [[Screening (medicine)|Screening]] should be done for first degree relatives of [[patients]] with APS for the presence of [[autoantibody]].
Effective measures for the [[primary prevention]] of autoimmune polyendocrine syndrome (APS) include [[patient education]] and [[[[Screening (medicine)|screening]]. Autoimmune polyendocrine syndrome may be [[inherited]] in [[autosomal recessive]] (APS type 1), [[autosomal dominant]] (APS type 2) or [[X linked inheritance|X linked]] fashion (APS type 3) and therefore educating relatives about presence of APS in [[family]] is necessary. In addition, [[Screening (medicine)|screening]] should be done for first degree relatives of [[patients]] with APS for the presence of [[autoantibody]].
 
==Primary Prevention==
==Primary Prevention==
Effective measures for the [[primary prevention]] of autoimmune polyendocrine syndrome (APS) include:
Effective measures for the [[primary prevention]] of autoimmune polyendocrine syndrome (APS) include:

Revision as of 13:29, 28 September 2017

Autoimmune polyendocrine syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune polyendocrine syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune polyendocrine syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune polyendocrine syndrome primary prevention

CDC on Autoimmune polyendocrine syndrome primary prevention

Autoimmune polyendocrine syndrome primary prevention in the news

Blogs on Autoimmune polyendocrine syndrome primary prevention

Directions to Hospitals Treating Autoimmune polyendocrine syndrome

Risk calculators and risk factors for Autoimmune polyendocrine syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measures for the primary prevention of autoimmune polyendocrine syndrome (APS) include patient education and [[screening. Autoimmune polyendocrine syndrome may be inherited in autosomal recessive (APS type 1), autosomal dominant (APS type 2) or X linked fashion (APS type 3) and therefore educating relatives about presence of APS in family is necessary. In addition, screening should be done for first degree relatives of patients with APS for the presence of autoantibody.

Primary Prevention

Effective measures for the primary prevention of autoimmune polyendocrine syndrome (APS) include:

References

Template:WH Template:WS